logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
logotype
logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
October 5, 2023

Sandoz receives European Commission approval for Tyruko, first and only biosimilar of Tysabri

by info@virtueinsight.comNews0 Comments

 

Sandoz, a global leader in generic and biosimilar medicines, announced that the European Commission (EC) granted marketing authorization for the first and only biosimilar Tyruko® (natalizumab), developed by Polpharma Biologics. The European approval for Tyruko comes a month after the US Food and Drug Administration (FDA) approval.

Tyruko was originally developed by Polpharma Biologics, with Sandoz acquiring the exclusive global commercialisation rights from the former in 2019. As per the agreement, Polpharma is responsible for the development, manufacturing, and supply of the drug, whilst Sandoz bears responsibility for distribution and commercialisation. According to Polpharma, Tyruko is authorized for adults with highly active relapsing remitting multiple sclerosis, the same indication as Tysabri in Europe. It has the same strength, dosage and intravenous administration as Tysabri.

Rebecca Guntern, President Europe, Sandoz, said: “Multiple sclerosis is a chronic condition with no cure at present and timely access to affordable, high-quality healthcare is therefore even more essential. Today’s approval brings us one step closer to reducing the burden of this disease for those living with multiple sclerosis in Europe by making the life-enhancing treatments they need more accessible.”

 Visit our Biosimilars conference – https://virtueinsight.com/event/biosimilars-congregation-2023/

anticounterfeit brandprotection Counterfeit DSCSA medical pharmaceutical pharma PharmaNews Serialization supplychain supplychainsecurity traceability trackandtrace VirtueInsight
prev

Italy’s Alfasigma to acquire Intercept Pharmaceuticals for $794m

next

Sandoz gains exclusive commercialization rights to biosimilar SB17 ustekinumab in Samsung deal

RELATED POSTS

August 19, 2024
News

Eli Lilly inaugurates R&D facility in Boston

read more
February 14, 2023
News

Spanish packaging firm Inden Pharma to expand footprint in India

read more

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

logotype

We strive to produce high quality conferences which include the latest topics which are delivered by world class leaders of the industry.

Facebook-fTwitterYoutubeLinkedin-inInstagramPinterest

Quick Links

About us
Contact us
Event Support
Careers
Privacy Policy
Terms & Conditions

Subscribe to our newsletter

    © 2025 Virtue Insight. All rights reserved.